Fluorescence lifetime-based tumor contrast enhancement using an EGFR antibody labeled near infrared fluorophore.

CONCLUSIONS: Our data suggest that FLT can significantly enhance tumor contrast using fluorescently labeled antibodies, thereby accelerating the efficient clinical application of these probes for margin assessment in image guided surgery and for highly specific detection of tumor receptors in-vivo. PMID: 31481509 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31481509?dopt=Abstract

Source: Clinical Genitourinary Cancer - September 2, 2019 Category: Cancer & Oncology Authors: Pal R, Kang H, Choi HS, Kumar ATN Tags: Clin Cancer Res Source Type: research